RPL32P5

Across TCGA pan-cancer cohorts, RPL32P5 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of RPL32P5’s most consistent transcriptional readouts.

The strongest signal is observed in cholangiocarcinoma (CHOL), where RPL32P5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL32P5 is over-expressed in tumor, although a few such as BRCA and STAD show the opposite, repressed pattern.

CHOL, BRCA, and STAD are the cancer types where RPL32P5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL32P5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CHOL	All	All	+0.247	.016	4	view →
BRCA	Female	II,III,IV	−0.092	.031	4	view →
STAD	All	IV	−0.423	.005	2	view →
PAAD	Male	All	−0.250	.006	2	view →
THCA	All	All	−0.161	.002	2	view →
LUSC	Male	III,IV	−0.142	.025	2	view →
LUAD	Male	III,IV	−0.168	.049	1	view →
KICH	All	All	−0.102	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

RPL32P5–CHOL

Open the CHOL breakdown →